GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

Listen to this article Pharmaceutical company Haleon will invest $54.2 million to upgrade its research and development facility in Richmond and launch an internship program in partnership with state ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target cells at ...

Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...